En la neoplasia intraepitelial cervical de alto grado | 14 JUL 18

Efecto del cribado con la prueba del VPH frente a la prueba de citología

Las mujeres basales con VPH negativo tuvieron una incidencia acumulativa significativamente menor de neoplasia intraepitelial cervical de alto grado a los 48 meses
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Arbyn  M, Rebolj  M, De Kok  IM,  et al.  The challenges of organising cervical screening programmes in the 15 old member states of the European Union.  Eur J Cancer. 2009;45(15):2671-2678. doi:10.1016/j.ejca.2009.07.016PubMedGoogle ScholarCrossref
  2. American Society of Clinical Oncology. Cervical cancer: statistics. Cancer.net. http://www.cancer.net/cancer-types/cervical-cancer/statistics. Published July 2017. Accessed April 14, 2018.
  3. Walboomers  JM, Jacobs  MV, Manos  MM,  et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;189(1):12-19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-FPubMed
  4. Garland  SM, Kjaer  SK, Muñoz  N,  et al.  Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience.  Clin Infect Dis. 2016;63(4):519-527. doi:10.1093/cid/ciw354PubMedGoogle ScholarCrossref
  5. Jeronimo  J, Castle  PE, Temin  S,  et al.  Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline.  J Glob Oncol. 2016;3(5):635-657. doi:10.1200/JGO.2016.006577PubMedGoogle ScholarCrossref
  6. Murphy  J, Kennedy  EB, Dunn  S,  et al.  HPV testing in primary cervical screening: a systematic review and meta-analysis.  J Obstet Gynaecol Can. 2012;34(5):443-452. doi:10.1016/S1701-2163(16)35241-0PubMedGoogle ScholarCrossref
  7. Ronco  G, Dillner  J, Elfström  KM,  et al; International HPV screening working group.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.  Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7PubMedGoogle ScholarCrossref
  8. Huh  WK, Ault  KA, Chelmow  D,  et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.  Gynecol Oncol. 2015;136(2):178-182. doi:10.1016/j.ygyno.2014.12.022PubMedGoogle ScholarCrossref
  9. Kulasingam  SL, Havrilesky  L, Ghebre  R, Myers  ER.  Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force: Evidence Syntheses, No. 86s. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
  10. Moyer  VA; US Preventive Services Task Force.  Screening for cervical cancer: US Preventive Services Task Force recommendation statement  [published correction appears in Ann Intern Med. 2013;158(11):852].  Ann Intern Med. 2012;156(12):880-891, W312. doi:10.7326/0003-4819-156-12-201206190-00424PubMedGoogle ScholarCrossref
  11. Coldman  AJ, Gondara  L, Smith  LW,  et al.  Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.  Br J Cancer. 2016;115(12):1487-1494. doi:10.1038/bjc.2016.368PubMedGoogle ScholarCrossref
  12. Ogilvie  GS, van Niekerk  DJ, Krajden  M,  et al.  A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).  BMC Cancer. 2010;10:111. doi:10.1186/1471-2407-10-111PubMedGoogle ScholarCrossref
  13. Ogilvie  GS, Krajden  M, van Niekerk  DJ,  et al.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial: the HPV FOCAL Study.  Br J Cancer. 2012;107(12):1917-1924. doi:10.1038/bjc.2012.489PubMedGoogle ScholarCrossref
  14. Ogilvie  GS, Krajden  M, van Niekerk


Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024